Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Tyrosine kinase inhibitors induce mesenchymal stem cell–mediated resistance in BCR-ABL + acute lymphoblastic leukemia

Blood (2015) 125 (19): 2968–2973.

https://doi.org/10.1182/blood-2014-05-576421

Published: 2015

Includes: Supplemental data

Journal Articles

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Blood (2013) 122 (11): 1923–1934.

https://doi.org/10.1182/blood-2013-03-492181

Published: 2013

Includes: Supplemental data

Journal Articles

The Role of c-Abl in Jak2 Activation in IL-3-Dependent Cells

Wenjing Tao, Ph.D., Xiaohong Leng, PhD, Ralph B. Arlinghaus, PhD

Blood (2011) 118 (21): 1672.

https://doi.org/10.1182/blood.V118.21.1672.1672

Published: 2011

Journal Articles

K562-R As a Model to Study Jak2 in a Non Bcr-Abl Addicted Cell Line

Bastianella Perazzona, Ph.D., Yu-Hsi Lin, Ralph B. Arlinghaus, PhD

Blood (2011) 118 (21): 4412.

https://doi.org/10.1182/blood.V118.21.4412.4412

Published: 2011

Journal Articles

Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells.

Donna DeGeer, MSc, Paolo Gallipoli, MD, Min Chen, PhD, Ivan Sloma, PhD, Heather Jorgensen, PhD, Donna Forrest, MD, Karen Lambie, Helen Nakamoto, Kyi Min Saw, Matthew Chan, Kathleen Newmarch, Leon Zhou, Ali G. Turhan, MD, PhD, Ralph B. Arlinghaus, PhD, Allen C. Eaves, MD, FRCPC, PhD, Connie J. Eaves, PhD, Tessa L. Holyoake, PhD, FRCP, FRCPath, Xiaoyan Jiang, MD, PhD

Blood (2010) 116 (21): 3404.

https://doi.org/10.1182/blood.V116.21.3404.3404

Published: 2010

Journal Articles

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

Blood (2010) 116 (21): 515.

https://doi.org/10.1182/blood.V116.21.515.515

Published: 2010

Journal Articles

The WD40-Repeats of Ahi-1 Oncogene Critical for Protein Interaction Between Ahi-1 and BCR-ABL Modulates Imatinib-Induced Apoptosis In BCR-ABL-Transduced Cells

Min Chen, PhD, Leon Zhou, PhD, Matthew Chan, PhD, Damian Lai, Ali G. Turhan, MD, PhD, Ralph B. Arlinghaus, PhD, Xiaoyan Jiang, MD, PhD

Blood (2010) 116 (21): 4181.

https://doi.org/10.1182/blood.V116.21.4181.4181

Published: 2010

Journal Articles

Jak2 Regulates Bcr-Abl In CD34+ Cells From Imatinib Mesylate-Resistant CML Patients.

Ajoy K. Samanta, Ph.D., Bastianella Perazzona, Ph.D., Sandip N. Chakraborty, Xiaoping Sun, MD, PhD, Hardik Modi, Ravi Bhatia, MD, Ralph B. Arlinghaus, PhD

Blood (2010) 116 (21): 1220.

https://doi.org/10.1182/blood.V116.21.1220.1220

Published: 2010

Journal Articles

Jak2 Phosphorylates Tyr 177 of Bcr-Abl Activating the Ras and PI-3 Kinase Pathways and Maintains Functional Levels of Bcr-Abl in Chronic Myelogenous Leukemia.

Ajoy K. Samanta, PhD, Sandip N. Chakraborty, Xiaoping Sun, M.D., Ph.D, Ellen Schlette, M.D., Waldemar Priebe, Ph.D., Ralph B. Arlinghaus, PhD

Blood (2009) 114 (22): 39.

https://doi.org/10.1182/blood.V114.22.39.39

Published: 2009

Journal Articles

Enhanced Jak2 Activation Correlates with β Chain Expression Leading to Phosphorylation of Tyrosine 177 of Bcr-Abl.

Wenjing Tao, Ph.D., Ajoy K. Samanta, Ph.D., Waldemar Priebe, Ph.D., Ralph B. Arlinghaus, Ph.D.

Blood (2009) 114 (22): 2170.

https://doi.org/10.1182/blood.V114.22.2170.2170

Published: 2009

Journal Articles

Role of BCR in Down-Modulation of BCR-ABL Oncogenicity in CML

Bastianella Perazzona, Ph.D., Yan Wang, M.D., Ralph B. Arlinghaus, PhD

Blood (2008) 112 (11): 3210.

https://doi.org/10.1182/blood.V112.11.3210.3210

Published: 2008

Journal Articles

Disruption of the Bcr-Abl/Jak2/HSP90 Network Complex Leading to Induction of Apoptosis in Drug-Resistant CML Cells by a New Compound WP1193

Ajoy K. Samanta, PhD, Sandip N. Chakraborty, Susmita Samanta, Ph.D., Yan Wang, M.D., Xiaoping Sun, MD, PhD, E. Schlette, Waldemar Priebe, Ph.D., Ralph B. Arlinghaus, PhD

Blood (2008) 112 (11): 3199.

https://doi.org/10.1182/blood.V112.11.3199.3199

Published: 2008

Journal Articles

Rooting into the Soil, a Model for the Role of Sox4 in Leukemia

Saradhi Mallampati, PhD, Baohua Sun, MD, PhD, Yun Gong, MD, Enze Wang, M. James You, MD, PhD, Hesham M. Amin, MD, MSC, Yupo Ma, MD, PhD, Haifa Shen, MD, PhD, Patrick Zweidler-McKay, MD, PhD, Dan Jones, MD, PhD, Cheng Yin, Armand Glassman, MD, Hagop M. Kantarjian, MD, Ralph B. Arlinghaus, PhD, Xiaoping Sun, MD, PhD

Blood (2008) 112 (11): 3794.

https://doi.org/10.1182/blood.V112.11.3794.3794

Published: 2008

Journal Articles

Vaccination with Leukemia Cell Expression Membrane Bound GM-CSF Overcomes the Host Immunosuppression Induced by Leukemia

Di Ling, Ralph B. Arlinghaus, PhD, Xiaoyang Ling, PhD

Blood (2008) 112 (11): 5435.

https://doi.org/10.1182/blood.V112.11.5435.5435

Published: 2008

Journal Articles

BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia

Kechen Ban, Yin Gao, Hesham M. Amin, Adrienne Howard, Claudia Miller, Quan Lin, Xiaohong Leng, Mark Munsell, Menashe Bar-Eli, Ralph B. Arlinghaus, Joya Chandra

Blood (2008) 111 (5): 2904–2908.

https://doi.org/10.1182/blood-2007-05-091769

Published: 2008

Journal Articles

Jak2 Regulates Lyn Tyrosine Kinase through Interference with the SET/PP2A/Shp1 Pathway and Inhibition of Jak2 Induced Apoptosis in BCR-ABL+ Imatinib-Sensitive and Resistant CML Cells.

Ajoy K. Samanta, PhD, Sandip Chakravorty, MS, Yan Wang, MD, Jorge Cortes, MD, Hagop Kantarjian, MD, Richard E. Champlin, MD, Danilo Perrotti, MD, PhD, Ralph B. Arlinghaus, PhD

Blood (2007) 110 (11): 3342.

https://doi.org/10.1182/blood.V110.11.3342.3342

Published: 2007

Journal Articles

Oncogenic Transformation of NIH 3T3 Fibroblasts by BCR-ABL Oncoprotein Requires the IL-3 Receptor.

Wenjing Tao, PhD, Hui Lin, MD, Tong Sun, MS, Ajoy K. Samanta, PhD, Ralph B. Arlinghaus, PhD

Blood (2007) 110 (11): 3370.

https://doi.org/10.1182/blood.V110.11.3370.3370

Published: 2007

Journal Articles

The ATP Competitor INNO-406 (NS-187) Inhibits Proliferation and Survival of Mouse Cells Expressing Several Immatinib Mesylate Resistant Bcr/Abl Mutants and Cells from CML Patients.

Wenjing Tao, PhD, Tong Sun, MS, Adam R. Craig, MD, PhD, Jorge E. Cortes, MD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD, Premkumar E. Reddy, PhD, Hagop M. Kantarjian, MD, Ralph B. Arlinghaus, PhD

Blood (2006) 108 (11): 2179.

https://doi.org/10.1182/blood.V108.11.2179.2179

Published: 2006

Journal Articles

Jak2: A Potential Therapeutic Target for Chronic Myelogenous Leukemia (CML).

Ajoy K. Samanta, PhD, Hui Lin, M.D., Tong Sun, M.S., Hagop Kantarjian, M.D., Ralph B. Arlinghaus, Ph.D.

Blood (2006) 108 (11): 2121.

https://doi.org/10.1182/blood.V108.11.2121.2121

Published: 2006

Journal Articles

Vaccination with Leukemia Cells Expressing Cell-Surface-Associated GM-CSF Blocks Leukemia Induction in Immunocompetent Mice.

Xiaoyang Ling, Ph.D, Yan Wang, M.D., Ralph B. Arlinghaus, Ph.D.

Blood (2004) 104 (11): 2531.

https://doi.org/10.1182/blood.V104.11.2531.2531

Published: 2004

NARROW

Tyrosine kinase inhibitors induce mesenchymal stem cell–mediated resistance in BCR-ABL + acute lymphoblastic leukemia

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

The Role of c-Abl in Jak2 Activation in IL-3-Dependent Cells

K562-R As a Model to Study Jak2 in a Non Bcr-Abl Addicted Cell Line

Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells.

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

The WD40-Repeats of Ahi-1 Oncogene Critical for Protein Interaction Between Ahi-1 and BCR-ABL Modulates Imatinib-Induced Apoptosis In BCR-ABL-Transduced Cells

Jak2 Regulates Bcr-Abl In CD34+ Cells From Imatinib Mesylate-Resistant CML Patients.

Jak2 Phosphorylates Tyr 177 of Bcr-Abl Activating the Ras and PI-3 Kinase Pathways and Maintains Functional Levels of Bcr-Abl in Chronic Myelogenous Leukemia.

Enhanced Jak2 Activation Correlates with β Chain Expression Leading to Phosphorylation of Tyrosine 177 of Bcr-Abl.

Role of BCR in Down-Modulation of BCR-ABL Oncogenicity in CML

Disruption of the Bcr-Abl/Jak2/HSP90 Network Complex Leading to Induction of Apoptosis in Drug-Resistant CML Cells by a New Compound WP1193

Rooting into the Soil, a Model for the Role of Sox4 in Leukemia

Vaccination with Leukemia Cell Expression Membrane Bound GM-CSF Overcomes the Host Immunosuppression Induced by Leukemia

BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia

Jak2 Regulates Lyn Tyrosine Kinase through Interference with the SET/PP2A/Shp1 Pathway and Inhibition of Jak2 Induced Apoptosis in BCR-ABL+ Imatinib-Sensitive and Resistant CML Cells.

Oncogenic Transformation of NIH 3T3 Fibroblasts by BCR-ABL Oncoprotein Requires the IL-3 Receptor.

The ATP Competitor INNO-406 (NS-187) Inhibits Proliferation and Survival of Mouse Cells Expressing Several Immatinib Mesylate Resistant Bcr/Abl Mutants and Cells from CML Patients.

Jak2: A Potential Therapeutic Target for Chronic Myelogenous Leukemia (CML).

Vaccination with Leukemia Cells Expressing Cell-Surface-Associated GM-CSF Blocks Leukemia Induction in Immunocompetent Mice.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only